Cumulus Neuroscience Presents NeuLogiq Data on Digital Endpoints for CNS Trials

Cumulus Neuroscience presented new data at the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference and the 38th European College of Neuropsychopharmacology (ECNP) Congress, announced in a press release. The company showcased findings from its NeuLogiq Platform, developed with biopharma partners to collect clinical-quality data from digital measurements in both clinical and home settings.

At the ECNP Congress, Cumulus presented interim results from a Phase 1b study conducted with Delix Therapeutics on DLX-001, a neuroplastogen for major depressive disorder. The study used the NeuLogiq Platform to assess pharmacodynamics, safety, and neurophysiological endpoints through portable EEG and cognitive testing.

A second ECNP poster reported results from the CNS-101 study, which followed patients with mild dementia and age-matched controls over 12 months. The data showed that home-based digital cognitive assessments were more sensitive to change than the ADAS-Cog 13 benchmark, enabling smaller trial cohorts and faster decision-making.

At ISCTM, the company also presented an analysis of 132 industry trials in Alzheimer’s disease and major depressive disorder. The modeling suggested that reducing cohort sizes by up to 50% could save time and costs in most trials, with smaller cohorts providing earlier readouts and lower recruitment demands.